Success Metrics

Clinical Success Rate

100.0%

Based on 7 completed trials

Completion Rate

100%(7/7)

Active Trials

0(0%)

Results Posted

71%(5 trials)

Phase Distribution

Ph phase_3

13%

Ph phase_2

25%

Ph phase_1

50%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution7 total trials

Phase 1Safety & dosage

4(57.1%)

Phase 2Efficacy & side effects

2(28.6%)

Phase 3Large-scale testing

1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

7 of 7 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(7)

Other(1)

Detailed Status

Completed7

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 14 (57.1%)

Phase 22 (28.6%)

Phase 31 (14.3%)

Trials by Status

completed788%

unknown113%

Recent Activity

0 active trials

Showing 5 of 8

completedphase_3

Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)

NCT02367040

completedphase_2

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas

NCT01660451

unknown

Expanded Access to Provide Copanlisib for Patients With Cancer Who Are Experiencing a Positive Response, as Determined by Their Doctors

NCT06238583

completedphase_1

Copanlisib Chinese PK Study

NCT03498430

completedphase_1

Study of Copanlisib in Hepatic or Renal Impairment

NCT03172884

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT02367040Phase 3

Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)

Completed

NCT01660451Phase 2

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas

Completed

NCT06238583

Expanded Access to Provide Copanlisib for Patients With Cancer Who Are Experiencing a Positive Response, as Determined by Their Doctors

Unknown

NCT03498430Phase 1

Copanlisib Chinese PK Study

Completed

NCT03172884Phase 1

Study of Copanlisib in Hepatic or Renal Impairment

Completed

NCT03655301Phase 1

Effect of Copanlisib on Metformin Pharmacokinetics and Pharmacodynamics

Completed

NCT02391116Phase 2

Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Completed

NCT00962611Phase 1

BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer

Completed

All 8 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 8